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Abstract
The progesterone receptor (PR) plays a key role in reproduction and is important in cancers of the
reproductive tract. Current PR antagonists usually compete for progestin binding in the PR ligand-
binding pocket and often exhibit cross-binding with other members of the steroid receptor family.
Using stably transfected cells expressing reporter genes, a set of ~150 theophylline analogues were
screened for their ability to inhibit progesterone, estrogen, glucocorticoid and androgen signaling.
The structure-activity studies presented here identify branched 8-alkylthio-6-thio-substitutions of
theophylline as selective PR inhibitors. 6-thio-8-(2-ethylbutyl)thiotheophylline (51), the most
extensively studied derivative, does not act by competing with progestins for binding in the
ligand-binding pocket of PR. It demonstrated the ability to inhibit the mouse mammary tumor
virus (MMTV)-luciferase reporter and endogenous PR-regulated alkaline phosphatase activity in
T47D breast cancer cells. Compound 51 is the lead member of a novel class of PR inhibitors that
act outside the PR ligand-binding pocket, thus serving as a novel probe to investigate PR action
and a lead for further development.
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1. Introduction
Progesterone plays a key role in regulating ovulation, uterine contractility, and mammary
tissue morphogenesis [1,2]. Most biological actions of progestins result from the activation
of the progesterone receptor (PR), a ligand-dependent transcription factor [3]. Hormone
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binding in the PR ligand-binding domain (LBD) induces a conformation that releases the
heat shock protein complex, enabling PR to more efficiently enter the nucleus and bind as a
homodimer to DNA response elements and regulate the transcription of target genes [4].
Depending on the tissue, estrogens and progestins can work synergistically or
antagonistically. While estrogen increases the levels of the two PR isoforms, PR-A and PR-
B, progestins binding to PR can suppress estradiol-stimulated estrogen receptor α (ERα)
activity [5]. PR antagonists have been developed as potential treatment options for
progesterone-dependent gynecological disorders, such as endometriosis and uterine and
breast cancers. In addition to their ability to inhibit the effects of endogenous progesterone,
PR antagonists repress estrogen-dependent proliferation of the mammary gland and uterus
[6,7]. Most antiprogestins, like mifepristone (RU486), are steroidal compounds that compete
with progestins binding in the ligand-binding pocket of PR. Classical PR antagonists bind
with high affinity and exhibit nanomolar potency, however, they often exhibit significant
binding to the glucocorticoid receptor (GR) [8,9].
In a high-throughput screen, our laboratory identified a small molecule inhibitor of steroid
receptor transactivation [10], 8-benzylsulfanylmethyl-1,3-dimethyl-3,7-dihydro-purine-2,6-
dione (TPBM), that belongs to a family of theophylline derivatives originally synthesized by
Dietz & Burgison [11,12]. A second small molecule characterized from this set, 8-((4-(4-
fluorophenyl)-4-oxobutyl)thio)-1,3-dimethyl-6-thioxo-6,7-dihydro-1H-purin-2(3H)-one
(TPSF), showed increased potency and a different mode of action than TPBM [13]. While
TPBM acts in part by blocking receptor binding to response element DNA, TPSF increases
the degradation of ligand-bound ERα. These compounds demonstrate the diversity of action
and specificity that this set of analogues present in modulating steroid receptor action.
Structure activity relationship (SAR) studies identify correlations between changes in
biological activity and molecular structure of a set of similar compounds.
In the course of our SAR studies, we gained the unusual capacity to evaluate the activity of
small molecules as inhibitors of transactivation mediated by 4 major steroid hormone
receptors: ER, PR, GR, and androgen receptor (AR). In our evaluation of this set of
structurally related theophylline derivatives, we identified 8-alkylthio-6-thiotheophyllines
that inhibited PR-mediated transactivation better than the parent compound. A subset of
small molecules, having saturated carbon-chain branching, exhibited a clear preference for
inhibiting PR relative to the other steroid receptors. Here, we describe a novel structural
motif that exhibits receptor specificity and describe a small molecule inhibitor of PR that
does not act by competing with progestins for binding to PR.
2. Experimental
2.1. Chemistry
2.1.1. General—Theophylline (1) was obtained from Sigma (St. Louis, MO). Compounds
2-55 were synthesized as described by Dietz and Burgison [11,12], and obtained from the
NCI Developmental Therapeutics Program. Solid compounds were dissolved in dimethyl
sulfoxide (DMSO) and stored at −20°C. The lead compound, 6-thio-8-(2-
ethylbutyl)thiotheophylline (51), has 85% chemical purity as determined by LC/MS.
2.2. Biology
2.2.1. Cell Culture—Unless otherwise indicated, cells were maintained at 37°C in 5%
CO2 in phenol red-free medium containing 1% penicillin/streptomycin and 10% fetal bovine
serum (FBS) (Atlanta Biological, Atlanta, GA). T47D/A1-2 breast cancer cells, stably
transfected to express additional GR and a mouse mammary tumor virus (MMTV)-
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luciferase reporter [14], were maintained in minimum essential medium (MEM)
supplemented with 10 mM HEPES, pH 7.4, 2 mM L-glutamine, and 0.2 mg/ml Geneticin
(G418). T47D-KBluc cells stably expressing an (ERE)3-luciferase reporter [15] were
maintained in RPMI 1640 supplemented with 10 mM HEPES, pH 7.5, 2 mM l-glutamine,
1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 1 mM sodium pyruvate. HeLa-AR1C-PSA-
Luc-A6 cells stably expressing AR and a prostate-specific antigen (PSA)-luciferase reporter
[13] were maintained in MEM supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 0.1 mg/ml hygromycin B (Roche Applied Science), and 0.5 mg/ml G418. T47D
cells were maintained in phenol red MEM supplemented with 10 mM HEPES, pH 7.4, and 2
mM glutamine. MCF-7 breast cancer cells were maintained in MEM supplemented with 10
mM HEPES, pH 7.4, 2 mM glutamine, and 5% FBS. Four days before experiments, cells
were transferred to the phenol red-free media described above, containing 10% dextran-
charcoal treated (CD)-CS (T47D/A1-2 and HeLa cells) or 10% CD-FBS (T47D-KBluc and
T47D cells) with hormone or compound added in DMSO. MCF-7 cells were transferred to
5% CD-FBS and assays were conducted in 10% CD-CS media.
2.2.2. Reporter Gene Assays—Assays for progesterone and glucocorticoid-dependent
transactivation were performed in T47D/A1-2 breast cancer cells. Estrogen and androgen-
dependent transactivations were assayed in T47D-KBluc and HeLa-A6 cells, respectively.
Cells were seeded overnight and then treated with 5 nM of progesterone (P), dexamethasone
(DEX), estradiol (E2), dihydrotestosterone (DHT), or ethanol vehicle - with or without 10
μM of the test compounds in DMSO. After 24 h, cells were washed once with phosphate
buffered saline (PBS) and lysed in passive lysis buffer (Promega, Madison WI). Luciferase
activity was determined using BrightGlo firefly luciferase reagent from Promega.
2.2.3. Alkaline Phosphatase Assay—T47D cells were seeded overnight and then
treated for 24 h with 2.5 nM P, with or without test compounds in DMSO. Cells were
washed once with PBS, lysed in harvest buffer (20 mM potassium phosphate, pH 7.8, 5 mM
MgCl2, 0.5% Triton X-100) and frozen at −70°C. 5 μl of thawed supernatant was removed
and assayed in a 96-well plate in 25 μl of assay buffer containing 100 mM diethanolamine,
pH 9.5, 1 mM MgCl2, 0.4 mM CSPD substrate (Applied Biosystems/Tropix) and 1X
Emerald II enhancer (Applied Biosystems/Tropix). After 1 h at room temperature,
luminescence was measured in the visible spectrum (emission max. 542 nm).
2.2.4. Enzyme Inhibition Assays—Assays using purified luciferase protein and the test
compounds were performed to rule out direct effects on luciferase enzyme activity. 0.05 ng
of purified luciferase protein was added to 5 μl OneGlo Buffer (Promega) in a 96 well plate
at a final concentration of 0.01 ng/μl luciferase protein. Each compound was diluted to 10
μM in buffer. 5 μl BrightGlo firefly luciferase reagent was added and incubated for 5
minutes before measuring luciferase activity. To test whether compounds directly affected
alkaline phosphatase (AlkP) activity, lysates from cells treated with 2.5 nM P, to induce
sufficient AlkP, were aliquoted and treated with 10 μM of each compound for 15 minutes.
Assay buffer (described above) was added to the lysate, incubated at room temperature for 1
h, and luminescence was measured.
2.2.5. RNA Isolation and Quantitative PCR—To induce alkaline phosphatase
expression, cells were maintained in medium containing 10 nM P and the indicated
concentrations of each compound in DMSO for 24 h. Total RNA was isolated using the
RNeasy Mini Kit (QIAGEN, Austin, TX) and 1 μg of RNA was reverse transcribed using
ProtoScript M-MuLV First Strand cDNA Synthesis Kit (New England BioLabs, Ipswich,
MA). Quantitative PCR was performed using Power SYBR Green PCR Master Mix
(Applied Biosystems, United Kingdom). mRNA levels were measured by quantitative RT-
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PCR as described [13]. Primers used in qRT-PCR were: AlkP, forward (5′-
TCGCCTACCAGCTCATGCATAACA) and reverse (5′-
TGAAGCTCTTCCAGGTGTCAACGA); and 36B4 internal standard, forward (5′-
GTGTTCGACAATGGCACAT) and reverse (5′-GACACCCTCCAGGAAGCGA).
2.2.6. Receptor Binding Assay—Relative binding affinities were determined in a
competitive radiometric assay as previously described [16-18] using 10 nM tritiated tracer,
unlabeled promegestone (R5020) as standard, and 10 nM purified full length recombinant
human PR-B (Pan Vera/Invitrogen, Carlsbad, CA). Incubations were for 18-24 h at 0°C.
Hydroxyapatite (BioRad, Hercules, CA) was used to absorb receptor-ligand complexes, and
free ligand was removed by washing with cold buffer. The data were analyzed using Prism
4.0. Binding affinities are expressed as relative binding affinity values with unlabeled R5020
set to 100%. The 3H tracer, [17α-methyl-3H]-R5020 (Perkin-Elmer, Boston, MA), binds PR
with a Kd of 0.4 nM.
2.2.7. Statistical Analysis—Results are expressed as mean ± standard error (SEM) of at
least three independent experiments. Student′s t-test was used for comparison of the means
between two groups. Significance was established when p < 0.05.
3. Results
The ability of 8-thioalkyltheophyllines to inhibit the activity of PR, ERα, GR and AR was
assessed using stably transfected cell lines, each expressing receptor-specific hormone
response elements linked to a luciferase reporter. PR and GR activities were assayed in
T47D/A1-2 breast cancer cells stably transfected to express a mammary tumor virus
(MMTV)-luciferase promoter. ERα activity was assayed in T47D-KBluc cells expressing a
reporter that contains 3 copies of the consensus estrogen response element (ERE)3-
luciferase. AR activity was assayed in HeLa-A6 cells stably transfected to express AR and a
prostate specific antigen (PSA)-luciferase reporter. Compounds were prepared as 10 mM
stocks in DMSO and tested at 10 μM. The final DMSO concentration (0.1%) was below the
0.3% (v/v) concentration associated with cytotoxic effects [10]. Receptor activity was
assayed in the presence of progesterone (P) for PR, 17β-estradiol (E2) for ER,
dexamethasone (DEX) for GR, and dihydrotestosterone (DHT) for AR. Table 1 summarizes
the percent transcriptional activity remaining in the presence of theophylline and 54 of its
structural derivatives. A table containing similar data for 93 more structurally diverse
analogues is provided in the Appendix.
Unmodified theophylline did not inhibit transactivation by any of the steroid receptors,
whereas several theophylline derivatives exhibited varying levels of inhibition. To increase
lipid solubility, oxygens in the X and Y positions were substituted with sulfurs. The
resulting 8-alkylthio-2-thio, 8-alkylthio-6-thio, and 8-alkylthio-2,6-dithiotheophyllines
displayed increased inhibition of transactivation, with 6-thio-substituted theophyllines being
the most potent inhibitors. For example, compounds 24 and 31 reduced steroid receptor
activity to a greater extent than their unsubstituted, 2-thio and 2,6-dithio counterparts (23-26
and 30-33, respectively).
The 6-thiotheophyllines with 8-alkylthio-substitutions 5-9 carbons in length (24, 31, and 34)
inhibited PR activity 41-58%, but lacked specificity. Efficacy and specificity for PR was
improved with compounds with alkyl branching. For example, 45 and 46, with a single
branched methyl group were moderately potent inhibitors of PR with no activity against ER,
GR, and AR. Methyl branching on the terminal carbon improved efficacy, but also inhibited
ER, as in the case of 48 and 49. Increasing the number of methyl groups with compound
49′s tertiary substitution inhibited PR activity 44%, but it also inhibited ER and GR.
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Compounds 51 and 52 had ethyl group side chains and inhibited PR to a greater extent than
compounds with methyl side chains. The location of the ethyl side chain was also slightly
more favorable in 51 and 52 which contain terminal branching.
Based on the results of the primary screen that indicated IC50s <10 μM and specificity for
PR, the alkyl-branched 8-alkylthio-6-thiotheophylline, compound 51, was selected as the
lead compound for further study. Its structure is shown in Figure 1A.
Since most current PR antagonists also inhibit GR, we assessed the potency and specificity
of compound 51 in dose-response studies that compared its ability to inhibit PR, ER, GR,
and AR (Figure 1B). In the luciferase reporter assays, 51 preferentially inhibited PR,
followed by ER, AR, and then GR. Its IC50 was 2.3 μM for PR, which was 2 to 6 fold lower
than for the other receptors (Figure 1C). Since PR and GR activities were assessed in a
single line of T47D cells, using the same MMTV-luciferase reporter, the absence of GR
inhibition is not an artifact due to use of different cells and promoters. In these cells,
compound 51 was a 6.1-fold more potent inhibitor of PR than GR, and compounds 48 and
52, which also contain this novel branched-chain alkyl motif, showed up to 10-fold
increased potency on PR than GR (Figure A.1).
We next tested the ability of the lead compound to inhibit progesterone induction of the
endogenous alkaline phosphatase (AlkP) gene in T47D human breast cancer cells [19,20]. In
these cells, AlkP enzyme activity was induced 23 fold by progesterone, but not by E2, DEX,
or DHT (data not shown). 51 potently inhibited progesterone induction of AlkP activity with
an IC50 of 1.2 μM and complete inhibition by 5 μM (Figure 2A).
We tested the possibility that the inhibition by 51 was an artifact due to direct inhibition of
luciferase or alkaline phosphatase enzyme activity. Compound 51 did not inhibit the
enzymatic activity of 0.05 ng of pure luciferase protein (t > 0.1). In lysates from cells in
which progesterone was used to induce alkaline phosphatase activity (16.5 ± 0.3 fold
induction relative to control), treatment with 51 failed to significantly inhibit activity (t >
0.3) (data not shown).
The specificity study in Fig. 1 used stably transfected reporter genes. To evaluate the effects
of 51 on the expression of an endogenous gene, we used qRT-PCR to investigate
progesterone induction of alkaline phosphatase mRNA. The 11.8 ± 1.6 fold induction in
mRNA levels was inhibited 74% by 5 μM of compound 51, and completely blocked at 10
μM (Figure 2B).
To compare 51′s ability to inhibit an ER-regulated endogenous gene, we analyzed pS2
mRNA. We tested the effect of compound 51 on ER at an early time, at which estrogen-ER
has not yet induced PR, thus the cells were maintained in medium containing 5 μM
compound 51 for only 2 hours. Under the same conditions in which 51 completely blocked
the progesterone induction of AlkP mRNA, it had no effect on the 17β-estradiol induction of
pS2 mRNA (Figure A.2). As a positive control, the estrogen antagonist, ICI 182,780
inhibited induction of pS2 mRNA. This data provides additional evidence that compound 51
preferentially inhibits PR-mediated gene expression.
Most PR antagonists compete with progesterone for binding in the ligand-binding domain of
the receptor. At functionally significant concentrations, compound 51 had little or no ability
to compete with the radio-labeled synthetic progestin, promegestone (R5020), for binding to
PR (Figure 3) and bound 4,700 fold less well than R5020. These results indicate that 51 is
unlikely to act by competing with progestins for binding in PR′s ligand-binding pocket. It
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remains possible that binding of 51, and other thiotheophylline derivatives, to a second site
on PR triggers a conformational change that influences the ability of PR to bind progestins.
4. Discussion
Previous studies showed that a set of 8-alkylthiotheophyllines displayed very weak
antitumor activity [11]. During a screen of a diversity test library, one of these compounds
was identified as an inhibitor of ERα action [10]. This set of small molecules was further
explored to identify a structural motif that confers preferential inhibition of steroid hormone
receptor activity. Replacing the oxygens in theophylline with sulfurs increased general
inhibition of steroid receptor activity. 6-thio substitutions were more effective than 2-thio or
2,6-dithio substitutions. 8-thioalkyl substitution further increased potency, with preferential
inhibition of PR as saturated chains 5-9 carbons in length were included. At shorter chain
lengths, inhibition was generally weak, while longer chain lengths were not specific for
inhibition of PR. Addition of saturated carbon-chain branching increased selectivity and
potency for inhibiting PR activity. Our SAR investigation of PR, ER, GR, and AR-
responsive reporter genes identified compound 51, which belongs to a set of saturated
branched 8-alkylthio-6-thio-substituted theophyllines that preferentially inhibited PR.
Compound 51 demonstrated pure antagonist effects – at concentrations of 30 μM and
higher, there was no observed agonist activity or decrease in antagonism as is often seen
with many selective PR modulators like RU486.
The LBDs of steroid receptors share a similar structure with a moderately conserved amino
acid sequence. Therefore, PR antagonists, like RU486 that binds in the ligand-binding
pocket, tend to discriminate poorly between receptors. Their ability to exert anti-
glucocorticoid activity limits the use of many PR antagonists. Our ability to identify small
molecules that selectively inhibit PR over GR activity was enhanced by testing them on the
same MMTV-luciferase reporter in T47D cells. Since the small molecules were assayed for
inhibition of PR and GR on the same promoter in the same cells, it is highly unlikely that
general toxicity is responsible for selective inhibition of PR by compound 51.
Ligand competition studies were used to evaluate the ability of 51 to compete with a
progestin for binding to the ligand-binding pocket of PR. Based on these studies, compound
51 and other branched 8-alkylthio-6-thio-substitutions likely exert their actions outside the
progestin binding pocket.
Compound 51 inhibited PR-induced enzyme activity of the stably transfected luciferase
reporter and endogenous alkaline phosphatase. Using quantitative RT-PCR, we also showed
that 51 inhibits the progesterone-PR induction of AlkP mRNA. Thus, compound 51 is a
noncompetitive inhibitor of PR-mediated gene expression.
PR, GR and AR are a subgroup of steroid receptors that can bind to the same DNA response
element. How target genes are selectively activated by individual receptors is not well
understood. Compound 51 may prove useful in elucidating differential effects of PR, GR
and AR on gene expression and in distinguishing actions mediated by PR from those
mediated by GR and other closely related members of the steroid receptor family.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix A. Supplementary Data
A table reporting the inhibition of steroid receptor action for the remaining 93 analogues of
theophylline and the dose response curves of 48 and 52, compounds closely related to lead







LBD ligand binding domain
PR progesterone receptor
SAR structure activity relationship
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➢ SAR of theophylline analogues against 4 major steroid receptors
➢ Novel motif preferentially inhibits progesterone receptor activity
➢ Inhibitor is pure antagonist of PR-mediated reporter and endogenous gene
activity
➢ Compound 51 does not display the properties of a competitive ligand
Aninye et al. Page 9














Compound 51 is a selective inhibitor of PR-mediated transactivation. (A) Structure of 51.
(B) Inhibition of transactivation by 51 in reporter gene assays. Reporter assays were
performed as described in the Experimental section. For each hormone, activity in the
absence of compound 51 was set as 100%. Error bars represent the SEM for at least three
experiments. (C) IC50s were calculated using Sigma Plot 11.0.
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Inhibition of progesterone-induced alkaline phosphatase enzyme activity (A) and mRNA
levels (B) by compound 51 in T47D cells. Alkaline phosphatase assays and qRT-PCR were
performed as described in the Experimental section. Error bars represent the SEM for at
least three experiments. AlkP activity in the absence of 51 was set to 100%. Enzyme activity
IC50 = 1.2 μM. AlkP mRNA in the absence of hormone and 51 was set to 1.0.
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Competitive binding of compound 51 with 10 nM R5020 to the progesterone receptor.
Competition assays were performed as described in the Experimental section. Error bars
represent the SEM for at least three experiments.
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